Physician profile
Zaid W Jabbar
NPI 1730351115
$1,151,133.39
in general payments reported to CMS, 2019-2025
62 companies · $152K in 2025
The $152K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206K · 2020: $126K · 2021: $112K · 2022: $181K · 2023: $164K · 2024: $209K · 2025: $152K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $409K · Travel and Lodging: $60K · Food and Beverage: $29K · Honoraria: $20K · Consulting Fee: $7,075 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $408,743.14 |
| Travel and Lodging | $60,178.71 |
| Food and Beverage | $29,247.53 |
| Honoraria | $19,925.00 |
| Consulting Fee | $7,075.00 |
| Education | $135.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $401,821.97 | 2019-2025 | Zepbound, Mounjaro, Trulicity |
| Novo Nordisk INC | $251,361.36 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $80,227.02 | 2021-2025 | |
| Amarin Pharma, INC. | $70,912.76 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70,090.73 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Allergan, INC. | $67,076.47 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $45,927.65 | 2024-2025 | Zenpep |
| Sunovion Pharmaceuticals INC. | $40,760.52 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $39,390.60 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $17,800.41 | 2023-2024 | Gvoke Hypopen, Recorlev |
| Currax Pharmaceuticals LLC | $16,495.74 | 2019-2025 | Contrave, Onzetra Xsail, Nexletol |
| Medicure Pharma INC. | $13,521.08 | 2019-2025 | Zypitamag |
| Esperion Therapeutics, INC. | $10,652.75 | 2020-2025 | Nexletol, Nexlizet |
| Takeda Pharmaceuticals U.S.A., INC. | $4,124.13 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $3,901.27 | 2019-2025 | Farxiga |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaid Jabbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.